ARWR:NSD-Arrowhead Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 65.37

Change

+0.67 (+1.04)%

Market Cap

USD 6.75B

Volume

0.51M

Avg Analyst Target

USD 97.00 (+48.39%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in Phase I/II clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase I/II clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase I/II clinical trial for treating liver diseases; ARO-ENaC, which is in Phase I/II clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase Ib for the treatment of clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-24.46 (-5.38%)

USD183.50B 53.71 41.56
BNTX BioNTech SE

-19.51 (-5.53%)

USD82.28B 18.73 15.10
REGN Regeneron Pharmaceuticals Inc

-7.61 (-1.18%)

USD69.15B 11.67 8.91
VRTX Vertex Pharmaceuticals Incorpo..

-1.48 (-0.80%)

USD48.02B 24.40 16.63
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-5.90 (-1.53%)

USD37.14B N/A N/A
SGEN Seagen Inc

-4.88 (-2.94%)

USD30.24B 51.86 39.11
GMAB Genmab A/S

-1.45 (-3.23%)

USD28.89B 73.39 8.17
RPRX Royalty Pharma plc

-0.03 (-0.08%)

USD22.54B 30.06 12.50
ALNY Alnylam Pharmaceuticals Inc

+0.45 (+0.24%)

USD22.22B N/A N/A

ETFs Containing ARWR

Symbol Name Weight Mer Price(Change) Market Cap
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.15 %

-1.30 (-0.58%)

USD1.52B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.10 %

-0.42 (-0.46%)

USD5.93B
XSU:CA iShares U.S. Small Cap In.. 0.00 % 0.36 %

-0.21 (-0.46%)

USD0.52B
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.08 %

-3.02 (-0.71%)

USD1.52B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.08 %

-1.68 (-0.48%)

USD5.93B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.30 %

+0.19 (+0.40%)

USD1.81B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.30 %

+0.08 (+0.13%)

USD1.81B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.30 %

+0.18 (+0.34%)

USD1.84B
XRS2:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.30 %

+0.85 (+0.31%)

USD1.63B
DRUP:F Lyxor Index Fund - Lyxor .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.81% 47% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.81% 47% F 23% F
Trailing 12 Months  
Capital Gain 45.54% 72% C- 60% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.54% 72% C- 58% F
Trailing 5 Years  
Capital Gain 805.40% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 805.40% 94% A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 179.73% 93% A 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 179.73% 93% A 96% A
Risk Return Profile  
Volatility (Standard Deviation) 187.86% 13% F 8% F
Risk Adjusted Return 95.68% 99% A+ 92% A-
Market Capitalization 6.75B 95% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 478.56 2% F 3% F
Price/Book Ratio 14.89 9% F 9% F
Price / Cash Flow Ratio -70.71 93% A 89% B+
EV/EBITDA 739.74 1% F 2% F
Management Effectiveness  
Return on Equity -27.09% 80% B- 37% F
Return on Invested Capital -26.40% 73% C 26% F
Return on Assets -13.00% 79% C+ 25% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.09 46% F 32% F
Short Percent 3.08% 70% C- 48% F
Beta 1.22 56% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.